Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 37

1.

A worldwide perspective of atypical pathogens in community-acquired pneumonia.

Arnold FW, Summersgill JT, Lajoie AS, Peyrani P, Marrie TJ, Rossi P, Blasi F, Fernandez P, File TM Jr, Rello J, Menendez R, Marzoratti L, Luna CM, Ramirez JA; Community-Acquired Pneumonia Organization (CAPO) Investigators.

Am J Respir Crit Care Med. 2007 May 15;175(10):1086-93. Epub 2007 Mar 1.

PMID:
17332485
2.

Empiric antibiotic coverage of atypical pathogens for community acquired pneumonia in hospitalized adults.

Robenshtok E, Shefet D, Gafter-Gvili A, Paul M, Vidal L, Leibovici L.

Cochrane Database Syst Rev. 2008 Jan 23;(1):CD004418. doi: 10.1002/14651858.CD004418.pub3. Review. Update in: Cochrane Database Syst Rev. 2012;9:CD004418.

PMID:
18254049
3.

Empiric antibiotic coverage of atypical pathogens for community acquired pneumonia in hospitalized adults.

Shefet D, Robenshtock E, Paul M, Leibovici L.

Cochrane Database Syst Rev. 2005 Apr 18;(2):CD004418. Review. Update in: Cochrane Database Syst Rev. 2008;(1):CD004418.

PMID:
15846713
4.

Appropriate outpatient macrolide use in community-acquired pneumonia.

Gotfried MH.

J Am Acad Nurse Pract. 2004 Apr;16(4):146, 148, 150 passim. Review.

PMID:
15137473
5.

Empiric antibiotic coverage of atypical pathogens for community-acquired pneumonia in hospitalized adults.

Eliakim-Raz N, Robenshtok E, Shefet D, Gafter-Gvili A, Vidal L, Paul M, Leibovici L.

Cochrane Database Syst Rev. 2012 Sep 12;(9):CD004418. doi: 10.1002/14651858.CD004418.pub4. Review.

PMID:
22972070
6.

How good is the evidence for the recommended empirical antimicrobial treatment of patients hospitalized because of community-acquired pneumonia? A systematic review.

Oosterheert JJ, Bonten MJ, Hak E, Schneider MM, Hoepelman IM.

J Antimicrob Chemother. 2003 Oct;52(4):555-63. Epub 2003 Sep 12. Review.

PMID:
12972448
7.

Empirical atypical coverage for inpatients with community-acquired pneumonia: systematic review of randomized controlled trials.

Shefet D, Robenshtok E, Paul M, Leibovici L.

Arch Intern Med. 2005 Sep 26;165(17):1992-2000. Review.

PMID:
16186469
8.

Community-acquired pneumonia: the U.S. perspective.

Niederman MS.

Semin Respir Crit Care Med. 2009 Apr;30(2):179-88. doi: 10.1055/s-0029-1202937. Epub 2009 Mar 18. Review.

PMID:
19296418
9.

Healthcare-associated pneumonia: diagnostic criteria and distinction from community-acquired pneumonia.

Falcone M, Venditti M, Shindo Y, Kollef MH.

Int J Infect Dis. 2011 Aug;15(8):e545-50. doi: 10.1016/j.ijid.2011.04.005. Epub 2011 May 26. Review.

10.

Optimizing treatment outcomes in severe community-acquired pneumonia.

de Castro FR, Torres A.

Am J Respir Med. 2003;2(1):39-54. Review.

PMID:
14720021
11.

Community-acquired pneumonia related to intracellular pathogens.

Cillóniz C, Torres A, Niederman M, van der Eerden M, Chalmers J, Welte T, Blasi F.

Intensive Care Med. 2016 Sep;42(9):1374-86. doi: 10.1007/s00134-016-4394-4. Epub 2016 Jun 8. Review.

PMID:
27276986
12.

Worldwide perspective of the quality of care provided to hospitalized patients with community-acquired pneumonia: results from the CAPO international cohort study.

Ramírez JA; Community-Acquired Pneumonia Organization Investigators.

Semin Respir Crit Care Med. 2005 Dec;26(6):543-52. Review.

PMID:
16388426
13.

Empiric treatment of ambulatory community-acquired pneumonia: always include treatment for atypical agents.

Marrie TJ.

Infect Dis Clin North Am. 2004 Dec;18(4):829-41. Review.

PMID:
15555827
14.

Importance of atypical pathogens of community-acquired pneumonia.

Plouffe JF.

Clin Infect Dis. 2000 Aug;31 Suppl 2:S35-9. Review.

PMID:
10984326
15.

Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: a systematic review and meta-analysis.

Asadi L, Sligl WI, Eurich DT, Colmers IN, Tjosvold L, Marrie TJ, Majumdar SR.

Clin Infect Dis. 2012 Aug;55(3):371-80. doi: 10.1093/cid/cis414. Epub 2012 Apr 16. Review.

PMID:
22511553
16.

Treatment of community-acquired pneumonia in hospitalised patients.

Mulazimoglu L.

Int J Antimicrob Agents. 2001;18 Suppl 1:S63-70. Review.

PMID:
11574198
17.

Burden of community-acquired pneumonia in North American adults.

File TM Jr, Marrie TJ.

Postgrad Med. 2010 Mar;122(2):130-41. doi: 10.3810/pgm.2010.03.2130. Review.

PMID:
20203464
18.

[Patients hospitalized with community-acquired pneumonia: a comparative study of outcomes by medical specialty area].

Capelastegui A, España PP, Quintana JM, Gorordo I, Martínez Urquiri A, Idoiaga I, Bilbao A.

Arch Bronconeumol. 2005 Jun;41(6):300-6. Review. Spanish.

19.

Tigecycline for the treatment of patients with community-acquired pneumonia requiring hospitalization.

Falagas ME, Metaxas EI.

Expert Rev Anti Infect Ther. 2009 Oct;7(8):913-23. doi: 10.1586/eri.09.73. Review.

PMID:
19803699
20.

Antimicrobial selection for community-acquired lower respiratory tract infections in the 21st century: a review of gemifloxacin.

Appelbaum PC, Gillespie SH, Burley CJ, Tillotson GS.

Int J Antimicrob Agents. 2004 Jun;23(6):533-46. Review.

PMID:
15194123

Supplemental Content

Support Center